Novogene Co., Ltd. (SHSE: 688315)
Health Care · Life Sciences Tools & Services · CN
CN¥19.77
-3.09% today · +25.5% 1Y
Novogene Co., Ltd. (SHSE: 688315) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $1.19B and employs 2,225 people.
Over the last twelve months the share price has gained 25.5%, trading between 11.46 and 21.49.
Tweenvest scores Novogene Co., Ltd. across four factors: quality 73/100, value 40/100, growth 19/100, dividend 8/100. Its strongest factor is quality.
688315 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.19B
- Revenue (TTM)
- $336.15M
- P/E
- 51.90
- EPS
- 0.38
- Dividend yield
- 0.23%
- Beta (5Y)
- 0.69
- 52-week high
- CN¥21.49
- 52-week low
- CN¥11.46
- Avg volume (3M)
- —
- Shares outstanding
- 405.06M
- Employees
- 2,225
- Next earnings
- —
About Novogene Co., Ltd.
Novogene Co., Ltd. is a global provider of comprehensive genomic services and advanced solutions. Its offerings span a wide array of genomic applications, including human, animal, plant, and microbial genome sequencing, alongside gene regulation and single-cell sequencing technologies. The company also specializes in cancer genomic profiling, whole exome sequencing (including clinical-grade versions), and FFPE RNA sequencing. Furthermore, Novogene develops proprietary tools such as NovoFocus, a next-generation sequencing (NGS)-based companion diagnostic for PARP inhibitor treatments, and NovoNeoantigen, a bioinformatics pipeline that identifies cancer neoantigens by analyzing whole exome and whole transcriptome sequencing data from matched tumor and normal samples. In a strategic collaboration, Novogene partners with Hummingbird Bioscience Pte. Ltd. to aid in the advancement of HMBD-001. This investigational anti-HER3 antibody is being assessed for its potential to treat diverse cancer types, notably those driven by NRG1-fusion. Established in 2011, Novogene Co., Ltd. operates from its headquarters in Beijing, China.
- ISIN
- CNE1000052X3
- Founded
- 2011
- Listed since
- Apr 13, 2021
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Indegene LimitedNSEI: INDGN | $1.48B | Rs593.50 | -2.54% |
| ChemoMetec A/SCPSE: CHEMM | $1.46B | Dkr555.50 | -2.11% |
| Akums Drugs and Pharmaceuticals LimitedNSEI: AKUMS | $1.29B | Rs813.10 | -0.79% |
| Beijing Hotgen Biotech Co., Ltd.SHSE: 688068 | $1.24B | CN¥94.47 | +2.81% |
| Maravai LifeSciences Holdings, Inc.NasdaqGS: MRVI | $1.18B | $7.21 | -8.73% |
| Beijing Sun-Novo Pharmaceutical Research Co., Ltd.SHSE: 688621 | $1.16B | CN¥71.00 | -2.41% |
| Gerresheimer AGXTRA: GXI | $1.12B | €28.42 | -2.00% |
| PharmaResources (Shanghai) Co., Ltd.SZSE: 301230 | $1.03B | CN¥38.48 | +0.79% |
Figures last refreshed Oct 4, 2026.